Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS

Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS: an Analysis of the Effectiveness of Steroid Therapy and a Comparison Between COVID-19 ARDS and ARDS From Other Etiologies

The goal of this observational study is to learn about the effect of steroid therapy in patients with COVID-19 ARDS. The main questions it aims to answer are:

• Differences between patients with COVID-19 ARDS before and after steroid treatment in BALF single cell landscape, as well as patients with different prognosis.
• Differences between COVID-19 and non COVID-19 ARDS patients in BALF single cell landscape.

Participants will Choose whether to use or not to utilize steroid treatment based on conditions.

Study Overview

• Status: Completed
• Conditions: Covid19; ARDS: Acute Respiratory Distress Syndrome
• Intervention / Treatment: Drug: steroid

Detailed Description

Collect BALF from COVID-19 and non-COVID-19 ARDS patients both before and during remission, then perform single-cell sequencing.

• Study Type: Observational
• Enrollment (Actual): 8

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100730
      • Peking Union Medical College Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

4 COVID-19 ARDS patients, 4 non-COVID-19 ARDS patients

Description

Inclusion Criteria:

• Severe ARDS patients

Exclusion Criteria:

• None

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
COVID-19 with steroid; COVID-19 ARDS patients with steroid treatment	Drug: steroid; Moderate- or high-dose steroids
COVID-19 without steroid; COVID-19 ARDS patients without steroid treatment
non-COVID-19 with steroid; non-COVID-19 ARDS patients with steroid treatment	Drug: steroid; Moderate- or high-dose steroids
non-COVID-19 without steroid; non-COVID-19 ARDS patients without steroid treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
single-cell analysis in BALF before treatment	collect BALF before and during treatment and perform single-cell sequencing	before treatment in ICU
single-cell analysis in BALF after treatment	collect BALF before and during treatment and perform single-cell sequencing	After treatment in ICU for 1-4 weeks

Collaborators and Investigators

• Sponsor: Peking Union Medical College Hospital
• Investigators: Study Director: Yun Long, MD, Peking union medical college hospital, ICU department

Study record dates

Study Major Dates

• Study Start (Actual): September 24, 2022
• Primary Completion (Actual): February 9, 2023
• Study Completion (Actual): March 15, 2023

Study Registration Dates

• First Submitted: June 2, 2023
• First Submitted That Met QC Criteria: July 5, 2023
• First Posted (Actual): July 6, 2023

Study Record Updates

• Last Update Posted (Actual): July 6, 2023
• Last Update Submitted That Met QC Criteria: July 5, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Respiration Disorders; Pneumonia, Viral; Pneumonia; Lung Diseases; Infant, Newborn, Diseases; Lung Injury; Infant, Premature, Diseases; COVID-19; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury
• Other Study ID Numbers: Covid20230601